2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-180547
    MRC71 3070832-68-4 98%
    MRC71 is a TRIMTAC degrader that recruits endogenous TRIM21 E3 ligase at one end and covalently binds to HaloTag-fusion target proteins at the other end. MRC71 selectively degrades oligomeric CAV1- and Cavin1-mEGFP-Halo, but not monomeric mEGFP-Halo, and exhibits a typical concentration-dependent degradation profile with a hook effect. MRC71 can be used to verify TRIMTAC ternary complex formation and state-selective degradation in cells.
    MRC71
  • HY-180552
    AChE-IN-104
    AChE-IN-104 (compound 3e) is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 8.01 µM. AChE-IN-104 also inhibits BChE and MAO-A with IC50s of 65.41 µM and 1.51 µM, respectively. AChE-IN-104 can be used for Alzheimer’s disease (AD) research.
    AChE-IN-104
  • HY-180576
    Nurr1/RXR agonist 1 2231746-53-3 98.26%
    Nurr1/RXR dual agonist 1 is a dual activator of Nurr1 (EC50 = 2.6 µM) and RXR with Ks of 0.6 and 1.1 µM, respectively. Nurr1/RXR dual agonist 1 exclusively activates the heterodimer response element DR5 by selectively destabilizing the Nurr1 homodimer and stabilizing the Nurr1:RXR heterodimer. Nurr1/RXR dual agonist 1 enhances expression of a specific subset of neuroprotective Nurr1 target genes while avoiding induction of genes associated with potential off-target effects in neuronal cells. Nurr1/RXR dual agonist 1 can be used for neurodegenerative diseases research.
    Nurr1/RXR agonist 1
  • HY-180582
    QND8 1778682-60-2
    QND8 is a selective and potent α7 nicotinic acetylcholine receptor (nAChR) agonist. QND8 can alleviate thermal hyperalgesia and mechanical hyperalgesia in carrageenan-induced inflammatory pain mouse model. QND8 can reduce the swelling of the mice feet, inhibit the release of pro-inflammatory factors at the inflammatory site, and prevent the infiltration of white blood cells. QND8 can be used for the research of inflammation and neurological disease, such as arthritis.
    QND8
  • HY-180584
    5-HT2A agonist 9 1555334-81-0
    5-HT2A agonist 9 (Compound I-53) is a 5-HT2A agonist with an EC₅₀ of 34 nM. 5-HT2A agonist 9 can be used for the study of mental disorders and central system disorders.
    5-HT2A agonist 9
  • HY-18060A
    Bradanicline hydrochloride 1111941-90-2 98%
    Bradanicline (TC-5619) tosylate is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline hydrochloride exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline hydrochloride possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline hydrochloride requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline hydrochloride is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough.
    Bradanicline hydrochloride
  • HY-180617
    5-HT2CR allosteric modulator 1 2376501-96-9
    5-HT2CR modulator 1 (Compound 3B) is a selective, positive ago-allosteric modulator of 5HT2CR with an EC50 of 8 nM. 5-HT2CR modulator 1 is also a selective 5HT2CR agonist with an EC50 of 25 nM. 5-HT2CR modulator 1 reduces food intake.
    5-HT2CR allosteric modulator 1
  • HY-180632
    D-Erythro-1-(imidazol-4-yl)glycerol 3-phosphate 36244-87-8
    D-Erythro-1-(imidazol-4-yl)glycerol 3-phosphate (D-Erythro-imidazole-glycerol 3-phosphate) is a metabolite in the histidine metabolism pathway. D-Erythro-1-(imidazol-4-yl)glycerol 3-phospha can serve as a biomarker for epilepsy.
    D-Erythro-1-(imidazol-4-yl)glycerol 3-phosphate
  • HY-180696
    Adenosine tetraphosphate 1062-98-2
    Adenosine tetraphosphate is a natural nucleotide present in many biological systems. Adenosine tetraphosphate produces a reduction in the intraocular pressure in normotensive rabbit eyes.
    Adenosine tetraphosphate
  • HY-180718
    Beta-alanyl-L-arginine 100869-33-8 98%
    Beta-alanyl-L-arginine (β-Alanyl-L-arginine) is an intestinal microbial metabolite. Beta-alanyl-L-arginine can be used for the study of schizophrenia.
    Beta-alanyl-L-arginine
  • HY-180731
    Gamma-glutamyl-beta-cyanoalanine 16051-95-9
    Gamma-glutamyl-beta-cyanoalanine (γ-Glutamyl-β-cyanoalanine), a dipeptide, is a neurotoxin found in Seeds of common vetch.
    Gamma-glutamyl-beta-cyanoalanine
  • HY-180779
    SR-1815 2636710-78-4 98%
    SR-1815 is a small molecule multi-kinase inhibitor. SR-1815, through mechanisms such as splicing regulation effectively restores the SynGAP protein to normal levels in the disease model with Syngap1 haploinsufficiency, thereby correcting the functional abnormalities at the synaptic and neuronal network levels caused by the deficiency of this gene. SR-1815 can be used for the study of brain diseases.
    SR-1815
  • HY-180783
    AChE/BChE/MAO-A-IN-1
    AChE/BChE/MAO-A-IN-1 (Compound 5c) is a multi-target inhibitor with IC₅₀ values for AChE, BChE, and MAO-A of 78.7, 22.63, and 0.84 μM respectively. AChE/BChE/MAO-A-IN-1 can be used for the research of Alzheimer's disease.
    AChE/BChE/MAO-A-IN-1
  • HY-180797
    S1R agonist/BChE-IN-1
    S1R agonist/BChE-IN-1 (Compound 7c) is a S1R (IC50: 19 nM) agonist and selective BChE (IC50: 37 nM for hBChE) inhibitor. S1R agonist/BChE-IN-1 can be used in the research of Alzheimer's disease.
    S1R agonist/BChE-IN-1
  • HY-180800
    Anti-inflammatory agent 110
    Anti-inflammatory agent 110 (Compound 7b) is a analgesic/anti-inflammatory agent. Anti-inflammatory agent 110 has a good binding affinity for COX-2. Anti-inflammatory agent 110 demonstrated potent analgesic and anti-inflammatory activities in the mouse hot plate test and the rat carrageenan edema model.
    Anti-inflammatory agent 110
  • HY-180802
    BCFTP 2781215-95-8
    BCFTP is a potent, orally active and selective human Mas-related G protein-coupled receptor X1 (MrgprX1)-positive allosteric modulator. BCFTP selectively potentiates MrgprX1 signaling in HEK293 cells. BCFTP alleviates specific neuropathic pain-related behaviors in a humanized MrgprX1 mouse model of chronic constrictive injury (CCI) in a MrgprX1-dependent manner. BCFTP synergistically enhances psychoactive substances analgesia in CCI MrgprX1 mice. BCFTP can be used for neuropathic pain research.
    BCFTP
  • HY-180806
    RIPK1-IN-39 3065634-42-3 98%
    RIPK1-IN-39 (compound 2) is a potent and selective RIPK1 inhibitor (IC50 = 69.40 nM) exhibiting >100-fold selectivity over RIPK3 (IC50 = 6946 nM). RIPK1-IN-39 protects HT-22 and HT-29 cells from necroptosis by inhibiting the phosphorylation and activation of the RIPK1-RIPK3-MLKL pathway. RIPK1-IN-39 demonstrates neuroprotective effects in a rat model of middle cerebral artery occlusion (MCAO). RIPK1-IN-39 can be used for acute ischemic stroke (AIS) research.
    RIPK1-IN-39
  • HY-180807
    MAPK-IN-6 98%
    MAPK-IN-6 (compound 116B) is a CNS-penetrant compound that inhibits the MAPK signaling pathway. MAPK-IN-6 reduces oxidative stress in SH-SY5Y neuronal cells by reducing ROS, restoring mitochondrial function, and inhibiting MAPK-driven inflammation. MAPK-IN-6 demonstrates profound neuroprotective efficacy in a rat tBCCAO/R model via ERK-P38-JNK signaling. MAPK-IN-6 can be used as a neuroprotective agent in ischemic stroke research.
    MAPK-IN-6
  • HY-180811
    ALK/HDAC-IN-2
    ALK/HDAC-IN-2 (Compound 19b) is an ALK/HDAC inhibitor with IC₅₀ values for ALK WT and total HDACs of 8 nM and 1.18 μM, respectively. ALK/HDAC-IN-2 exhibits inhibitory activity against ALK mutants G1202R, F1174L, and L1196M, with IC₅₀ values of 2.74, 9.23, and 34.28 nM, respectively. ALK/HDAC-IN-2 shows potent and selective inhibition against HDAC1 (IC₅₀ = 0.24 μM), while its inhibitory activity against HDAC7, HDAC6, and HDAC11 is weak (IC₅₀ > 10 μM). ALK/HDAC-IN-2 has broad-spectrum anti-proliferative activity against various cancer cells, inducing cell cycle arrest and apoptosis. ALK/HDAC-IN-2 can be used for the study of neuroblastoma.
    ALK/HDAC-IN-2
  • HY-180819
    AChE/BChE-IN-33
    AChE/BChE-IN-33 (Compound 3N) is a dual-target inhibitor of AChE and BChE, with IC50 values of 12.81 and 44.54 nM respectively. AChE/BChE-IN-33 exhibits selective cytotoxicity against SH-SY5Y cells. AChE/BChE-IN-33 can be used for the study of Alzheimer's disease and neuroblastoma.
    AChE/BChE-IN-33
Cat. No. Product Name / Synonyms Application Reactivity